The Japan cancer vaccines market size is expected to reach USD 4,633.44 million by 2034, according to a new study by Polaris Market Research. The report “Japan Cancer Vaccines Market Size, Share, Trends, Industry Analysis Report: By Type (Prevention Vaccines, Treatment Vaccines, and Oncolytic Viruses), Indication, and Patient Type– Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Japan cancer vaccines are immunotherapies designed to prevent or treat cancer by stimulating the body's immune system to recognize and eliminate cancer cells. These vaccines are classified into preventive vaccines, which help reduce cancer risk, and therapeutic vaccines, which target existing malignancies. The market includes various vaccine types, such as peptide-based, dendritic cell-based, and oncolytic virus-based therapies, developed through extensive research in oncology and immunotherapy.
The Japan cancer vaccines market growth is driven by the rising prevalence of cancer, increasing government support for immunotherapy research, and advancements in biotechnology. Growing investments in personalized medicine and targeted cancer therapies create opportunities for innovation in vaccine development. Emerging Japan cancer vaccines market trends include the integration of artificial intelligence in vaccine research, expanding clinical trials for novel immunotherapies, and partnerships between pharmaceutical companies and research institutions. Additionally, improved regulatory pathways for cancer immunotherapies and rising awareness about immunization against virus-induced cancers, such as HPV-related cervical cancer, contribute to market expansion.
Japan Cancer Vaccines Market Report Highlights:
The Japan cancer vaccines market, by type, is segmented into prevention vaccines, treatment vaccines, and oncolytic viruses. The preventive vaccines dominated the market share in 2024. These vaccines aim to prevent cancers associated with viral infections, such as the human papillomavirus (HPV) vaccine, which reduces the risk of cervical cancer.
Based on indication, the market is segmented into prostate, cervical, and others. The cervical cancer segment dominated the Japan cancer vaccines market share in 2024. This prominence is attributed to the high prevalence of human papillomavirus (HPV) infections, which are strongly linked to cervical cancer development.
The market, by patient type, is segmented into pediatric and adult. The adult segment held a larger share of the Japan cancer vaccines market revenue in 2024 as cancer prevalence is higher in older populations. This prominence is also primarily attributed to the increasing incidence of human papillomavirus (HPV) infections among adults, which has created the demand for preventive vaccines targeting HPV-related cancers. However, pediatric cancer vaccines are gradually expanding with growing research into immunotherapies for childhood cancers.
The market features several active companies contributing to advancements in oncology. A few notable players include Aduro BioTech, Inc.; Astellas Pharma, Inc.; Bristol-Myers Squibb; Tella, Inc.; Oncolys BioPharma Inc.; CYTLIMIC; Takeda Pharmaceutical Company Limited; Takara Bio; Daiichi Sankyo Company Limited; Merck & Co., Inc.; Moderna, Inc.; Chugai Pharmaceutical Co., Ltd.; Otsuka Holdings Co., Ltd.; Eisai Co., Ltd.; and Shionogi & Co., Ltd.
Polaris Market Research has segmented the Japan cancer vaccines market report on the basis of type, indication, and patient type:
By Type Outlook (Revenue – USD Million, 2020–2034)
Prevention Vaccines
Treatment Vaccines
Oncolytic Viruses
By Indication Outlook (Revenue – USD Million, 2020–2034)
Prostate
Cervical
Others
By Patient Type Outlook (Revenue – USD Million, 2020–2034)
Pediatric
Adult
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source
- 4. Japan Cancer Vaccines Market Insights
- 4.1. Japan Cancer Vaccines Market – Market Snapshot
- 4.2. Japan Cancer Vaccines Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing incidence of cancer in Japan
- 4.2.1.2. Government initiatives and research programs
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Stringent regulatory approval processes
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Japan Cancer Vaccines Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Japan Cancer Vaccines Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Japan Cancer Vaccines Market, by Type, 2020–2034 (USD Million)
- 5.3. Prevention Vaccines
- 5.3.1. Japan Cancer Vaccines Market, by Prevention Vaccines, by Region, 2020–2034 (USD Million)
- 5.4. Treatment Vaccines
- 5.4.1. Japan Cancer Vaccines Market, by Treatment Vaccines, by Region, 2020–2034 (USD Million)
- 5.5. Oncolytic Viruses
- 5.5.1. Japan Cancer Vaccines Market, by Oncolytic Viruses, by Region, 2020–2034 (USD Million)
- 6. Japan Cancer Vaccines Market, by Indication
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Japan Cancer Vaccines Market, by Indication, 2020–2034 (USD Million)
- 6.3. Prostate
- 6.3.1. Japan Cancer Vaccines Market, by Prostate, by Region, 2020–2034 (USD Million)
- 6.4. Cervical
- 6.4.1. Japan Cancer Vaccines Market, by Cervical, by Region, 2020–2034 (USD Million)
- 6.5. Others
- 6.5.1. Japan Cancer Vaccines Market, by Others, by Region, 2020–2034 (USD Million)
- 7. Japan Cancer Vaccines Market, by Patient Type
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Japan Cancer Vaccines Market, by Patient Type, 2020–2034 (USD Million)
- 7.3. Pediatric
- 7.3.1. Japan Cancer Vaccines Market, by Pediatric, by Region, 2020–2034 (USD Million)
- 7.4. Adult
- 7.4.1. Japan Cancer Vaccines Market, by Adult, by Region, 2020–2034 (USD Million)
- 8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
- 9. Company Profiles
- 9.1. Astellas Pharma Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Chugai Pharmaceutical Co., Ltd.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Daiichi Sankyo Company, Limited
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Eisai Co., Ltd.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Kaken Pharmaceutical Co., Ltd.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Kissei Pharmaceutical Co., Ltd.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Kyowa Kirin Co., Ltd.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Meiji Seika Pharma Co., Ltd.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Mitsubishi Tanabe Pharma Corporation
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Nippon Kayaku Co., Ltd.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook